Previous 10 | Next 10 |
home / stock / lly / lly articles
Eli Lilly And Co’s (NYSE:LLY) shares are trading higher after an advisory committee to the U.S. Food and Drug Administration (FDA) delivered ...
On Monday, major U.S. indices closed positively, with the Dow Jones Industrial Average rising by 0.2% to 38,868.04. The S&P 500 increased by 0....
Eli Lilly and Co (NYSE:LLY) shared detailed results from the SYNERGY-NASH phase 2 study on Saturday. This trial involved 190 patients, both with an...
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have s...
The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors. Wh...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the dat...
Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its...
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL Int...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
2024-07-02 16:00:05 ET Terence Flynn from Morgan Stanley issued a price target of $1,023.00 for LLY on 2024-07-02 14:30:00. The adjusted price target was set to $1,023.00. At the time of the announcement, LLY was trading at $906.1521. The overall price target consensus i...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participan...